The management of low-stage non-seminomatous germ cell tumors by Louise Lim, Thomas Powles

Get full text

Patient and Healthcare Professional Perspectives from ESMO 2022 on Bladder and Kidney Cancer: A Podcast by Alex Filicevas, Thomas Powles

Get full text

Patient needs in advanced Renal Cell Carcinoma: What are patients’ priorities and how well are we meeting them? by Rick Harris, Kate Oake, Robert Hawkins, Robert Jones, Thomas Powles, David Montgomery

Get full text

Role of Perioperative Immune Checkpoint Inhibitors in Muscle Invasive Bladder Cancer by Saachi Chhaya, Isabella Watts, Kenrick Ng, Rami Mustapha, Thomas Powles, Anand Sharma, Nikhil Vasdev

Get full text

445 The relationship between immune-related adverse events (irAEs) and ctDNA status: exploratory analysis from IMvigor010 by Thomas Powles, Sanjeev Mariathasan, Rajat Mohindra, G Scott Chandler, Corey Carter, Katrin Madjar, Bogdana I Balas, Laurent Essioux, Viraj Degaonkar

First Evidence of Activity of Enfortumab Vedotin on Brain Metastases in Urothelial Cancer Patients by Christof Vulsteke, Laurens De Cocker, Alfonso Gómez de Liaño, Cristina Montesdeoca, Astrid De Meulenaere, Lieselot Croes, Danielle Delombaerde, Bernadett Szabados, Thomas Powles

Get full text

Japanese subgroup analysis of EV‐301: An open‐label, randomized phase 3 study to evaluate enfortumab vedotin versus chemotherapy in subjects with previously treated locally advance... by Nobuaki Matsubara, Junji Yonese, Takahiro Kojima, Haruhito Azuma, Hiroaki Matsumoto, Thomas Powles, Jonathan E. Rosenberg, Daniel P. Petrylak, Maria Matsangou, Chunzhang Wu, Mary Campbell, Mayumi Yamashiro

Get full text

Outcomes based on plasma biomarkers in METEOR, a randomized phase 3 trial of cabozantinib vs everolimus in advanced renal cell carcinoma by Thomas Powles, Toni K. Choueiri, Robert J. Motzer, Eric Jonasch, Sumanta Pal, Nizar M. Tannir, Sabina Signoretti, Rajesh Kaldate, Christian Scheffold, Evelyn Wang, Dana T. Aftab, Bernard Escudier, Daniel J. George

Get full text

Correction to: Outcomes based on plasma biomarkers in METEOR, a randomized phase 3 trial of cabozantinib vs everolimus in advanced renal cell carcinoma by Thomas Powles, Toni K. Choueiri, Robert J. Motzer, Eric Jonasch, Sumanta Pal, Nizar M. Tannir, Sabina Signoretti, Rajesh Kaldate, Christian Scheffold, Evelyn Wang, Dana T. Aftab, Bernard Escudier, Daniel J. George

Get full text

The potential of using circulating tumour cells and their gene expression to predict docetaxel response in metastatic prostate cancer by Caitlin R. Davies, Tianyu Guo, Tianyu Guo, Edwina Burke, Elzbieta Stankiewicz, Elzbieta Stankiewicz, Lei Xu, Lei Xu, Xueying Mao, Glenda Scandura, Prabhakar Rajan, Prabhakar Rajan, Prabhakar Rajan, Prabhakar Rajan, Karen Tipples, Constantine Alifrangis, Constantine Alifrangis, Akhila Ganeshi Wimalasingham, Myria Galazi, Shanthini Crusz, Thomas Powles, Thomas Powles, Alistair Grey, Alistair Grey, Alistair Grey, Tim Oliver, Sakunthala Kudahetti, Greg Shaw, Greg Shaw, Greg Shaw, Daniel Berney, Jonathan Shamash, Yong-Jie Lu

Get full text

Long-term outcomes with nivolumab plus ipilimumab versus sunitinib in first-line treatment of patients with advanced sarcomatoid renal cell carcinoma by Chung-Wei Lee, Thomas Powles, Sabina Signoretti, David F McDermott, Sumanta K Pal, Toni K Choueiri, Brian I Rini, Saby George, Robert J Motzer, Frede Donskov, Scott S Tykodi, Nizar M Tannir, Saurabh Gupta, Ruiyun Jiang

Get full text

Biomarker analysis from CheckMate 214: nivolumab plus ipilimumab versus sunitinib in renal cell carcinoma by Jin Yao, Thomas Powles, David F McDermott, Toni K Choueiri, Petra Ross-MacDonald, Simon Papillon-Cavanagh, Robert J Motzer, M Brent McHenry, Megan Wind-Rotolo, Ron Ammar, Yann-Alexandre Vano, Saurabh Gupta, Celine Han, Shruti S Saggi

Get full text

The Efficacy of Sunitinib Treatment of Renal Cancer Cells Is Associated with the Protein PHAX In Vitro by Rafia S. Al-Lamki, Nicholas J. Hudson, John R. Bradley, Anne Y. Warren, Tim Eisen, Sarah J. Welsh, Antony C. P. Riddick, Fiach C. O’Mahony, Arran Turnbull, Thomas Powles, SCOTRRCC Collaborative, Antonio Reverter, David J. Harrison, Grant D. Stewart

Get full text

266 Tumour mutation burden (TMB) and efficacy outcomes in the phase III DANUBE study of advanced urothelial carcinoma (UC) by Weimin Li, Ross Stewart, Thomas Powles, Joaquim Bellmunt, Feng Xiao, Ashok Gupta, Jill Walker, Melissa de los Reyes, Matthew Galsky, Sophie Wildsmith, Anne L’Hernault, Hannah Bye, Philip He, Qu Zhang, Rajiv Raja, Wendy Levin, Alexandra Drakaki, Michiel van der Heijden

Indications and Outcomes for Deferred Cytoreductive Nephrectomy Following Immune Checkpoint Inhibitor Combination Therapy: Can Systemic Therapy be Withdrawn in Patients with No Evi... by Elisabeth E. Fransen van de Putte, Luna van den Brink, Mohamed A. Mansour, Johannes C. van der Mijn, Sofie Wilgenhof, Johannes V. van Thienen, John B.A.G. Haanen, Ekaterini Boleti, Thomas Powles, Patricia J. Zondervan, Niels M. Graafland, Axel Bex

Get full text

PRISM protocol: a randomised phase II trial of nivolumab in combination with alternatively scheduled ipilimumab in first-line treatment of patients with advanced or metastatic rena... by Hannah L. Buckley, Fiona J. Collinson, Gemma Ainsworth, Heather Poad, Louise Flanagan, Eszter Katona, Helen C. Howard, Geraldine Murden, Rosamonde E. Banks, Joanne Brown, Galina Velikova, Tom Waddell, Kate Fife, Paul D. Nathan, James Larkin, Thomas Powles, Sarah R. Brown, Naveen S. Vasudev

Get full text

Expression-based subtypes define pathologic response to neoadjuvant immune-checkpoint inhibitors in muscle-invasive bladder cancer by A. Gordon Robertson, Khyati Meghani, Lauren Folgosa Cooley, Kimberly A. McLaughlin, Leigh Ann Fall, Yanni Yu, Mauro A. A. Castro, Clarice S. Groeneveld, Aurélien de Reyniès, Vadim I. Nazarov, Vasily O. Tsvetkov, Bonnie Choy, Daniele Raggi, Laura Marandino, Francesco Montorsi, Thomas Powles, Andrea Necchi, Joshua J. Meeks

Get full text

Neoadjuvant pazopanib and molecular analysis of tissue response in renal cell carcinoma by Christopher G. Wood, James E. Ferguson III, Joel S. Parker, Dominic T. Moore, Jennifer G. Whisenant, Susan J. Maygarden, Eric M. Wallen, William Y. Kim, Mathew I. Milowsky, Kathryn E. Beckermann, Nancy B. Davis, Scott M. Haake, Jose A. Karam, Dante S. Bortone, Benjamin G. Vincent, Thomas Powles, W. Kimryn Rathmell

Get full text

Molecular residual disease detection in resected, muscle-invasive urothelial cancer with a tissue-based comprehensive genomic profiling–informed personalized monitoring assay by Thomas Powles, Amanda Young, Halla Nimeiri, Russell W. Madison, Alexander Fine, Daniel R. Zollinger, Yanmei Huang, Chang Xu, Ole V. Gjoerup, Vasily N. Aushev, Hsin-Ta Wu, Alexey Aleshin, Corey Carter, Nicole Davarpanah, Viraj Degaonkar, Pratyush Gupta, Sanjeev Mariathasan, Erica Schleifman, Zoe June Assaf, Geoffrey Oxnard, Priti S. Hegde

Get full text

Neoadjuvant vs. Adjuvant Chemotherapy in Muscle Invasive Bladder Cancer (MIBC): Analysis From the RISC Database by Gabriella Del Bene, Fabio Calabrò, Diana Giannarelli, Elizabeth R. Plimack, Lauren C. Harshman, Evan Y. Yu, Simon J. Crabb, Sumanta Kumar Pal, Ajjai S. Alva, Thomas Powles, Ugo De Giorgi, Neeraj Agarwal, Aristotelis Bamias, Sylvain Ladoire, Andrea Necchi, Ulka N. Vaishampayan, Günter Niegisch, Joaquim Bellmunt, Jack Baniel, Matthew D. Galsky, Cora N. Sternberg

Get full text